Leung, Alex K. K.
Genga, Kelly Roveran http://orcid.org/0000-0002-6500-2926
Topchiy, Elena
Cirstea, Mihai
Shimada, Tadanaga
Fjell, Chris
Russell, James A.
Boyd, John H.
Walley, Keith R.
Funding for this research was provided by:
Michael Smith Foundation for Health Research (17171)
Gouvernement du Canada | Canadian Institutes of Health Research (FDN 154311)
Article History
Received: 13 February 2019
Accepted: 27 June 2019
First Online: 22 July 2019
Competing Interests
: J.H.B. has a patent Methods and Uses for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors (PCT/CA2013/000488) pending. J.A.R. receives financial support from Grifols, Asahi Kesai Pharmaceuticals of America (AKPA), La Jolla Pharmaceuticals, Ferring Pharmaceuticals, Cubist Pharmaceuticals, Leading Biosciences, CytoVale Inc., Cyon Therapeutics Inc., and Molecular You Corp.